Table 2. Base-case scenario results.

	Life year (years)	Total cost ($)	Cost in PFS ($)	Cost in PP ($)	Cost in terminal ($)	QALY	QALY in PFS	QALY in PP	Increase cost-effectiveness ratio ($/QALY)
Discount =3%
Docetaxel	1.415569	33,086.801	16,584.98243	13,985.57082	2,516.248171	0.699023008	0.415285922	0.283737086
Pembrolizumab 2 mg/kg	2.506085	87,134.788	65,950.3899	18,731.75113	2,452.646488	1.200180446	0.820153592	0.380026854	107,846.3214
Pembrolizumab 10 mg/kg	3.268327	369,326.82	341,301.0169	25,622.14013	2,403.662537	1.448864396	0.929046401	0.519817995	448,414.8563
Discount =0
Docetaxel	1.586283	35,962.074	16,848.39896	16,494.32379	2,619.351697	0.756516116	0.42188184	0.334634276
Pembrolizumab 2 mg/kg	2.608329	100,049.463	75,925.75792	21,508.11567	2,615.589261	1.380579307	0.944226001	0.436353306	102,693.7485
Pembrolizumab 10 mg/kg	3.407474	433,056.416	399,721.7948	30,732.713	2,601.908083	1.71157748	1.088076977	0.623500503	415,778.8773

PFS, progression-free survival; PP, post-progression; QALY, quality-adjusted life year.